0001144204-18-037986.txt : 20180711 0001144204-18-037986.hdr.sgml : 20180711 20180711160549 ACCESSION NUMBER: 0001144204-18-037986 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180711 DATE AS OF CHANGE: 20180711 EFFECTIVENESS DATE: 20180711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biostage, Inc. CENTRAL INDEX KEY: 0001563665 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455210462 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-316577 FILM NUMBER: 18948789 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: (774) 233-7300 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 FORMER COMPANY: FORMER CONFORMED NAME: Harvard Apparatus Regenerative Technology, Inc. DATE OF NAME CHANGE: 20121204 D 1 primary_doc.xml X0708 D LIVE 0001563665 Biostage, Inc. 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 (774) 233-7300 DELAWARE None Harvard Apparatus Regenerative Technology, Inc. Corporation true James McGorry 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Executive Officer Director Chief Executive Officer Thomas McNaughton 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Executive Officer Chief Financial Officer Hong Yu 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Executive Officer President William Fodor 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Executive Officer Chief Scientific Officer Jing Chen 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Director James Shmerling 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Director Wei Zhang 84 OCTOBER HILL ROAD SUITE 11 HOLLISTON MA MASSACHUSETTS 01746 Director Biotechnology Decline to Disclose 06b false 2018-06-29 false true false 900000 900000 900000 0 false 1 0 54000 This represents a financial advisory fee pursuant to this offering. 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3. false Biostage, Inc. /s/ Thomas McNaughton Thomas McNaughton Chief Financial Officer 2018-07-11